The 2 linked references in paper D. Naskhletashvili R., V. Gorbunova A., A. Bekyashev Kh., V. Karakhan B., E. Moskvina A., E. Prozorenko V., Д. Насхлеташвили Р., В. Горбунова А., А. Бекяшев Х., В. Карахан Б., Е. Москвина А., Е. Прозоренко В. (2015) “РОЛЬ ТАРГЕТНОЙ ТЕРАПИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ ПОЧКИ С МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГА // ROLE OF TARGETED THERAPY IN THE COMBINATION TREATMENT OF PATIENTS WITH KIDNEY CANCER AND METASTATIC BRAIN INVOLVEMENT” / spz:neicon:ogsh:y:2012:i:4:p:19-25

  1. Elfiky A.A., Cho D.C., McDermott D.F. et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear cell renal carcinoma. Urol Oncol 2010; doi:10.1016/j. urolonc.2010.01.008; [Epub ahead of print].
  2. Kim A., McCully C., Cruz R. et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs 2010; doi:10.1007/s10637-010-9585-1; [Epub ahead of print].